Wednesday, August 15, 2018
Home Research & Development

Research & Development

In a randomized phase III trial patients with surgically removed pancreatic cancer who received modified FOLFIRINOX (mFOLFIRINOX), a chemotherapy regimen containing four different medicines including oxaliplatin, leucovorin, and irinotecan administered intravenously (IV) at day 1, followed by 5-fluorouracil via...
A randomized, phase III trial, called PREOPANC-1, funded in part by the Dutch Cancer Society KWF/Koningin Wilhelmina Fonds, found that people who received chemotherapy with radiation, also known as chemoradiotherapy, before pancreatic cancer surgery had better disease-free survival than...
In a phase II study, IMvigor 210, atezolizumab (Tecentriq™; Genentech, a member of the Roche Group) shrank tumors (objective response rate, ORR) in 24% (n=28) of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received...
Prostate cancer patients and survivors who maintain a moderate to high level of physical activity may improve their survival prognosis, according to research presented at the Annual Meeting of the American Association for Cancer Researchheld in NewOrleans,April 16-20, 2016 “Our...
Researchers from the Okayama University in Japan report photo immunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the February 2016...
Many patients around the globe do not have access to proper opioid analgesics - critical to the effective relief and management of cancer pain. This lack of access represent a serious public health problem. These conclusions are from the...
Based on trial results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145; Merck and Endocyte), an investigational folate small molecule drug conjugate or SMDC, published in the Journal of Clinical Oncology(JCO), the official journal of the American...
For many years, scientists have observed that breast tumor from certain breast cancer patients with aggressive - metastatic - undergo epithelial-to-mesenchymal transition or EMT which makes them resistant to therapies targeted to the primary cancer. They also observed that...
Positive data from the second stage of the phase III CLL11 trial, conducted in cooperation between Roche and the German CLL Study Group, compared obinutuzumab (Gazyva™, Genentech/Roche), a glyco-optimised type II CD20 blocker also known as GA101, in combination...
In a large prospective study published online in the October 22, 2013 issue of the British Journal of Cancer(BMJ), researchers looked at the association between nut consumption and risk of pancreatic cancer among 75,680 women in the Nurses' Health...

Related articles